Pertussis is routinely diagnosed with real-time PCR based on insertion sequence IS481, which is not specific for Bordetella pertussis. We conducted a retrospective study using real-time PCRs specific for Bordetella pertussis and for Bordetella holmesii on 177 samples positive for IS481 PCR. Bordetella holmesii DNA was detected in 20.3% samples collected from adolescents and adults.
Bordetella holmesii is known to be responsible for bacteremia in hyposplenic patients, including those affected by sickle cell anemia, and has also been isolated from the sputum of patients with pertussis symptoms (4, 6, 10) . The diagnosis of Bordetella infections routinely involves real-time PCR (9) . Two insertion sequences, IS481 and IS1001, are commonly used as PCR targets because numerous copies are present in the bacterial genomes and this contributes to the sensitivity of these tests. However, (i) IS481 is present in the genome of B. holmesii isolates and some B. bronchiseptica isolates and is therefore not specific for B. pertussis and (ii) IS1001 is present in the genome of some B. bronchiseptica and is therefore not specific for B. parapertussis (9) .
The aim of this retrospective study was to identify the Bordetella species in biological samples positive for IS481 collected between 2009 and 2010 in four French laboratories. To identify the species, we used previously developed specific "in-house" real-time PCR. These real-time PCRs are based on the amplification of the promoter of the pertussis toxin operon (ptxAPr-based PCR) specific for B. pertussis (1) and of the recA gene (RecA-based PCR) specific for B. holmesii (2) . We also used a real-time PCR based on the BP3385 gene (BP3385-based PCR), which was initially described as specific for B. pertussis (5) but was subsequently shown to score positive for some B. bronchiseptica isolates (8) . This PCR can replace the ptxA-Prbased PCR to detect B. pertussis carrying a deletion of the whole ptx operon, which is pertinent because such B. pertussis isolates can circulate (3). We also used the IS1001 PCR to analyze coinfections (9) . The primers used to perform the "in-house" PCRs are listed in Table 1 .
The analytical sensitivity of the different assays was determined by using a series of 10-fold dilutions of B. pertussis Tohama, B. parapertussis 12822, and B. holmesii BHO1 DNAs (7, 9) . Each dilution was tested three times independently. The limits of detection per PCR in our conditions were 0.5 CFU and 1 CFU for IS481-and IS1001-based PCRs, respectively, using the Argene kits (catalog no. 69-0011B for IS481-based PCR and 71-012 for IS1001-based PCR; Argene, Verniolle, France), 30 CFU for the in-house ptxA-Pr-based PCR, 30 CFU for the in-house BP3385-based PCR, and 50 CFU for the in-house RecA-based PCR. Because of the difference of sensitivity between the routine IS481-and IS1001-based PCRs and the specific in-house PCRs we decided to analyze only biological samples with a threshold cycle (C T ) of Ͻ30 as assessed with IS481 PCR. We selected 177 biological samples from nasopharyngeal aspirates or swabs from suspected cases of pertussis. DNA was extracted using the High Pure PCR template preparation kit (Roche), the EZ1 DNA tissue kit (Qiagen), or easyMAG (bioMérieux). The C T values obtained with the IS481 PCR for these 177 samples were all between 8 and 30. We performed the four PCRs on all samples. A total of 163 (92%) samples scored positive by ptxA-Prbased PCR and BP3385-based PCR and negative by RecAbased PCR and IS1001-based PCR and were therefore determined to contain B. pertussis DNA.
One (0.6%) sample was positive by ptxA-Pr-based PCR, BP3385-based PCR, and IS1001-based PCR and negative by RecA-based PCR and was therefore determined to contain B. pertussis and B. parapertussis or B. bronchiseptica DNA.
A total of 12 (6.8%) samples scored positive by RecA-based PCR and negative by ptxA-Pr-based PCR, BP3385-based PCR, and IS1001-based PCR and were therefore determined to contain B. holmesii DNA.
Two (1.1%) samples were ptxA-Pr-based PCR negative but positive by BP3385-based PCR. These samples may contain DNA not carrying the ptx operon as previously described (3) or a quantity of DNA below the limit of detection of the ptxA-Pr target or B. bronchiseptica DNA.
No sample was both positive for the ptxA-Pr-based PCR and negative for the BP3385-based PCR.
Information concerning birth date was available for the 177 patients. We defined three groups: 0 to 9 (n ϭ 119), 10 to 17 (n ϭ 20), and 18 or more years old (n ϭ 39). Among the 59 patients older than 9 years, 20.3% were identified as being infected with B. holmesii and not B. pertussis; 6 of these cases were between 10 and 17 years of age (30% of the cases analyzed in the age group) and 6 were between 18 and 48 years of age (15.3% of the analyzed cases in this age group). Although the number of samples analyzed is small, these findings demonstrate that B. holmesii is frequently present in biological samples from adolescents and adults who have respiratory symptoms clinically diagnosed as pertussis. Generally, this species is isolated in blood cultures of immunocompromised or asplenic patients but also, although less frequently, in patients with pertussis syndromes (9) . This is consistent with previous reports describing B. holmesii infection in patients with pertussis-like symptoms (4, 6, 10) . Surprisingly, no patient under 9 years of age was carrying B. holmesii DNA, suggesting a lower rate of transmission of B. holmesii than of B. pertussis from adults to infants. All samples collected from infants or young children were confirmed as containing B. pertussis, and only one case of coinfection (B. pertussis-B. parapertussis or B. bronchiseptica) was observed (a 5-year-old patient). The two patients confirmed as carrying either B. pertussis or B. bronchiseptica were 1 and 60 years of age. Because no information is available concerning the vaccine status or animal contacts of these two patients, conclusions are difficult to formulate.
In conclusion, we confirm that B. holmesii is indeed a bacterial species associated with pertussis-like symptoms: 20% of patients (12 patients over 9 years of age) previously identified as having pertussis were infected with B. holmesii. No coinfection with B. pertussis and B. holmesii was found. The number of samples we tested is small, but the proportion of B. holmesiipositive samples was higher than previously described (2). In our study, all cases of B. holmesii detection were in adolescents and adults and not in infants. At present, we do not know whether B. holmesii is either a human respiratory pathogen or an opportunist bacterium carried mostly by adolescents and adults and detected only during an episode of cough due to another Bordetella infection or another microorganism. We do not know whether this phenomenon is new and due to the decrease in the incidence of pertussis, following the introduction of pertussis boosters, or one that has been simply overlooked in the past. Before 2005, only the B. pertussis-specific PCR was routinely used in France. Since then, most laboratories routinely use the IS481-based PCR because of its high sensitivity, and it is therefore difficult to choose between the two hypotheses. Due to the limitations of retrospective investigation, this study is unable to confirm the presence of B. holmesii by culture. It is, however, very important to emphasize that isolation of this organism would strengthen the recognition of B. holmesii and its potential clinical and epidemiological implications in whooping cough-like illness.
Surveillance of B. holmesii should be pursued, and all clinicians and epidemiologists need to be aware of this observation. Indeed, correct identification using specific real-time PCR for each Bordetella species and culture of this pathogen is important for the active surveillance of Bordetella infections in the whole population, particularly in adolescents and adults. 5Ј-CCA ACG CGC ATG CGT GCA  GAT TCG TC-3Ј  PT2  5Ј-CCC TCT GCG TTT TGA TGG TGC  CTA TTT TA-3Ј  PT- 
